当前位置:首页 - 行情中心 - 和元生物(688238) - 财务分析 - 现金流量表

和元生物

(688238)

  

流通市值:42.02亿  总市值:42.12亿
流通股本:6.47亿   总股本:6.49亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金230,587,707.26136,779,461.9448,630,562.32257,555,229.9
  收到其他与经营活动有关的现金24,394,908.067,829,467.275,750,101.7528,663,348.18
  经营活动现金流入小计254,982,615.32144,608,929.2154,380,664.07286,218,578.08
  购买商品、接受劳务支付的现金113,800,573.5875,921,738.6340,109,253.66143,608,557.22
  支付给职工以及为职工支付的现金147,150,972.3599,760,850.5849,882,134.21188,568,976.14
  支付的各项税费10,200,087.866,953,183.213,466,683.7211,675,367.15
  支付其他与经营活动有关的现金70,241,102.5344,889,477.5126,994,825.1944,960,622.53
  经营活动现金流出小计341,392,736.32227,525,249.93120,452,896.78388,813,523.04
  经营活动产生的现金流量净额-86,410,121-82,916,320.72-66,072,232.71-102,594,944.96
二、投资活动产生的现金流量:
  收回投资收到的现金489,000,00080,000,00030,000,000313,685,358.8
  取得投资收益收到的现金787,161.28437,939.0917,532.181,439,028.55
  处置固定资产、无形资产和其他长期资产收回的现金净额11,420--1,321,910
  收到的其他与投资活动有关的现金---34,604,082.48
  投资活动现金流入小计489,798,581.2880,437,939.0930,017,532.18351,050,379.83
  购建固定资产、无形资产和其他长期资产支付的现金70,423,301.1354,436,480.8131,655,989.08126,243,412.59
  投资支付的现金594,650,00099,650,00081,650,000314,000,000
  取得子公司及其他营业单位支付的现金---116,922.06
  支付其他与投资活动有关的现金---21,221,013.74
  投资活动现金流出小计665,073,301.13154,086,480.81113,305,989.08461,581,348.39
  投资活动产生的现金流量净额-175,274,719.85-73,648,541.72-83,288,456.9-110,530,968.56
三、筹资活动产生的现金流量:
  吸收投资收到的现金1,650,0001,650,0001,650,000-
  其中:子公司吸收少数股东投资收到的现金-1,650,000--
  取得借款收到的现金700,000,000185,000,000115,000,000280,000,000
  筹资活动现金流入小计701,650,000186,650,000116,650,000280,000,000
  偿还债务支付的现金300,150,500151,217,000118,483,500101,044,371.26
  分配股利、利润或偿付利息支付的现金8,097,601.684,840,165.32,434,797.598,348,247.28
  支付其他与筹资活动有关的现金3,282,873.933,208,679.7674,194.17101,803,652.48
  筹资活动现金流出小计311,530,975.61159,265,845.06120,992,491.76211,196,271.02
  筹资活动产生的现金流量净额390,119,024.3927,384,154.94-4,342,491.7668,803,728.98
四、汇率变动对现金及现金等价物的影响-156,201.52-109,542.46-50,528.32-20,263.68
五、现金及现金等价物净增加额128,277,982.02-129,290,249.96-153,753,709.69-144,342,448.22
  加:期初现金及现金等价物余额290,551,803.61290,551,803.61290,551,803.61434,894,251.83
  期末现金及现金等价物余额418,829,785.63161,261,553.65136,798,093.92290,551,803.61
补充资料:
  净利润--101,559,075.74--234,810,012.67
  资产减值准备-1,737,710.45-22,903,467.32
  固定资产和投资性房地产折旧-47,263,663.72-93,224,306.35
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-47,263,663.72-93,224,306.35
  无形资产摊销-1,161,717.31-2,086,518.97
  长期待摊费用摊销-1,360,266.78-2,720,533.56
  处置固定资产、无形资产和其他长期资产的损失---1,072,763.43
  公允价值变动损失--248,450.39--86,487.4
  财务费用-5,161,538.85-8,634,944.92
  投资损失-806,043.2--6,089,808.86
  递延所得税-332,119.93-1,598,591.27
  其中:递延所得税资产减少-938,775.48--1,431,170.67
    递延所得税负债增加--606,655.55-3,029,761.94
  存货的减少--12,926,920.45-1,341,469.12
  经营性应收项目的减少--37,932,665.26--33,990,586.92
  经营性应付项目的增加-5,281,086.41-33,167,175.79
  其他-1,514,995.06-1,339,323.69
  现金的期末余额-161,261,553.65-290,551,803.61
  减:现金的期初余额-290,551,803.61-434,894,251.83
  现金及现金等价物的净增加额--129,290,249.96--144,342,448.22
公告日期2026-10-292026-08-252026-04-282026-04-21
审计意见(境内)标准无保留意见
TOP↑